J. García-Chávez

发表

Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia.

G. Galindo-Rodríguez, J. Vela-Ojeda, A. Rosas-Cabral, 2004, Stem cells and development.

IFN-α as Induction and Maintenance Treatment of Patients Newly Diagnosed with Waldenström's Macroglobulinemia

J. A. Aviña-Zubieta, J. Vela-Ojeda, M. Vadillo-Buenfil, 2002 .

von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage

A. Majluf-Cruz, Patricia Gomez-Rosas, J. García-Chávez, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis

A. Majluf-Cruz, J. Vela-Ojeda, L. Montiel-Cervantes, 2007, Annals of Hematology.

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor

A. Majluf-Cruz, H. Mayani, J. Vela-Ojeda, 2008, Annals of Hematology.

Awareness regarding venous thromboembolism among internal medicine practitioners in Mexico: a national cross‐sectional study

A. Majluf-Cruz, F. Espinosa-Larrañaga, J. García-Chávez, 2012, Internal medicine journal.

Activated Protein C Resistance and Factor V Leiden in Mexico

A. Majluf-Cruz, R. Guardado-Mendoza, J. Vela-Ojeda, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia.

J. Vela-Ojeda, M. G. Garcia-Ruiz Esparza, L. Montiel-Cervantes, 2018, Archives of medical research.

Acquired hemophilia.

A. Majluf-Cruz, J. García-Chávez, 2020, Gaceta medica de Mexico.

Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.

A. Majluf-Cruz, H. Mayani, J. Vela-Ojeda, 2010, Stem cells and development.

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

J. Vela-Ojeda, A. Rosas-Cabral, M. G. Garcia-Ruiz Esparza, 2002, Annals of Hematology.

Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle‐income Latin American country

L. Villarreal-Martínez, J. García-Chávez, A. I. González-Ávila, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Musculoskeletal evaluation in severe haemophilia A patients from Latin America

M. Ozelo, P. Villaça, M. Solano, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[Economic impact of hemophilia type A and B in Mexico].

A. Majluf-Cruz, J. García-Chávez, R. Gasca-Pineda, 2016, Gaceta medica de Mexico.

Important decrease in invariant natural killer T, CD4+ regulatory T cells, CD8+ regulatory T cells, gamma-delta T cells, and CD4+ T lymphocytes in HIV-negative patients with hemophilia.

A. Majluf-Cruz, J. Vela-Ojeda, M. G. Garcia-Ruiz Esparza, 2020, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma

A. Majluf-Cruz, J. Vela-Ojeda, M. G. Garcia-Ruiz Esparza, 2020, Leukemia & lymphoma.

The C677T Polymorphism of the Methylenetetrahydrofolate Reductase Gene Is Associated with Idiopathic Ischemic Stroke in the Young Mexican-Mestizo Population

A. Majluf-Cruz, I. Ibarra-González, J. Vela-Ojeda, 2010, Cerebrovascular Diseases.

Risk Factors for Thrombosis Development in Mexican Patients.

A. Majluf-Cruz, E. Hernández-Zamora, J. Vela-Ojeda, 2015, Annals of vascular surgery.

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

M. Steurer, D. Cines, B. Chong, 2017, Haematologica.

Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.

J. Vela-Ojeda, A. Rosas-Cabral, F. Tripp-Villanueva, 2000, Archives of medical research.

Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

A. Majluf-Cruz, J. Vela-Ojeda, L. Montiel-Cervantes, 2019, International journal of hematology.

[Primary immune thrombocytopenia in adults in Mexico: national characteristics and the relation to international literature].

D. Gómez-Almaguer, J. García-Chávez, G. Gutiérrez-Espíndola, 2014, Gaceta medica de Mexico.

[Prevalence of bacterial infections and patterns of bacterial susceptibility among patients with fever, neutropenia, and hematological neoplasias].

J. L. Fuentes-Allen, A. Majluf-Cruz, J. Vela-Ojeda, 2011, Gaceta medica de Mexico.

Abo Blood Group, Atherothrombotic Comorbidities, and COVID-19: A Case-Control Study of their Association in the Mexican Population

A. Majluf-Cruz, J. Pascual, J. Vela-Ojeda, 2021, Archives of Medical Research.

[Long-term response to rituximab in a patient with acquired hemophilia].

A. Majluf-Cruz, J. Vela-Ojeda, J. García-Chávez, 2011, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

von Willebrand's disease in Mexico: a pilot study

J. García-Chávez, A. I. González-Ávila, M. Moreno-Hernández, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of Refractory Chronic Immune Thrombocytopaenic Purpura (ITP) with Rituximab: Report of a Cases Series.

J. Vela-Ojeda, R. Ovilla-Martínez, J. García-Chávez, 2005 .